학술논문

Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study
Document Type
Academic Journal
Source
Arthritis Research & Therapy. August 28, 2014, Vol. 16
Subject
Statistics
Analysis
Development and progression
Research
Comparative analysis
Health aspects
Cancer -- Development and progression -- Comparative analysis
Arthritis -- Development and progression -- Comparative analysis -- Research
Histochemistry -- Comparative analysis -- Analysis -- Statistics -- Health aspects -- Research
Language
English
ISSN
1478-6354
Abstract
Author(s): Sung Hae Chang[sup.1] , Jin Kyun Park[sup.1] , Yun Jong Lee[sup.1] , Ji Ae Yang[sup.1] , Eun Young Lee[sup.1] , Yeong Wook Song[sup.1] and Eun Bong Lee[sup.1] Introduction Rheumatic [...]
Introduction Rheumatic diseases (RDs) are associated with different cancers; however, it is unclear whether particular cancers are more prevalent in certain RDs. In the present study, we examined the relative incidence of several cancers in a single homogeneous cohort of patients with different RDs. Methods Patients (N = 3,586) diagnosed with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), dermatomyositis (DM) or polymyositis were included. Cancer diagnosis was based on histopathology. The 2008 Korean National Cancer Registry served as the reference for calculating standardized incidence ratios (SIRs). Results During the follow-up period of 31,064 person-years, 187 patients developed cancer. RA and SLE patients showed an increased risk of non-Hodgkin's lymphoma (SIR for RA patients = 3.387, 95% confidence interval (CI) = 1.462 to 6.673; SIR for SLE patients = 7.408, 95% CI = 2.405 to 17.287). SLE patients also had a higher risk of cervical cancer (SIR = 4.282, 95% CI = 1.722 to 8.824). SSc patients showed a higher risk of lung cancer (SIR = 4.917, 95% CI = 1.977 to 10.131). Endometrial cancer was increased only in patients with DM (SIR = 30.529, 95% CI = 3.697 to 110.283). RA patients had a lower risk for gastric cancer (SIR = 0.663, 95% CI = 0.327 to 0.998). The mean time between the RD and cancer diagnoses ranged from 0.1 to 16.6 years, with the shortest time observed in patients with DM (2.0 [+ or -] 2.1 years). Conclusions Different RDs are associated with particular cancers. Thus, cancer surveillance tailored to specific RDs might be beneficial.